{Reference Type}: Journal Article
{Title}: The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma.
{Author}: Rathi VK;Soler ZM;Schlosser RJ;Workman AD;Chapurin N;Rowan NR;Dusetzina SB;
{Journal}: Int Forum Allergy Rhinol
{Volume}: 14
{Issue}: 7
{Year}: 2024 Jul 11
{Factor}: 5.426
{DOI}: 10.1002/alr.23344
{Abstract}: <B>CONCLUSIONS: </B>In 2021, Medicare spending on biologics was $926 million in Part B (FFS) and $1.3 billion in Part D (FFS/MA). Between 2017 and 2021, annual Medicare spending on biologics increased by approximately 200%. Between 2023 and 2025, Medicare Part D OOP costs for biologics will decrease by an estimated 50%-60%.